Company Overview of Edge Therapeutics, Inc.
Edge Therapeutics, Inc., a hospital-focused biopharmaceutical company, designs and develops implantable technology for direct delivery of therapeutic compounds to the site of brain injury. Its drugs cover therapeutic areas, such as spontaneous brain hemorrhage, traumatic brain injuries, and brain surgeries. The company develops NimoGel and NimoVent to prevent delayed cerebral ischemia, a catastrophic delayed complication after subarachnoid hemorrhage. Its therapeutics are delivered to patients in the United States and internationally. The company was founded in 2009 and is based in New Providence, New Jersey.
139 South Street
New Providence, NJ 07974
Founded in 2009
Key Executives for Edge Therapeutics, Inc.
Chief Accounting and Operations Officer
Compensation as of Fiscal Year 2014.
Edge Therapeutics, Inc. Key Developments
Edge Therapeutics, Inc. Obtains $10 Million Venture Loan Facility with Hercules Technology Growth Capital, Inc
Sep 8 14
Edge Therapeutics, Inc. announced that it has obtained up to $10 million in venture debt financing from Hercules Technology Growth Capital, Inc. to support the continued development of EG-1962, the company's lead product candidate. Edge is developing EG-1962 to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage. The company believes that EG-1962 can become the new standard of care for patients suffering from a ruptured brain aneurysm who receive an intraventricular catheter. The $10 million in funding from Hercules is in the form of secured indebtedness. Payments under the loan agreement are interest only for 12 months, followed by 30 equal monthly payments of principal and interest through the scheduled maturity date on March 1, 2018.
Edge Therapeutics Initiates Enrollment of Second Cohort in Phase 1/2 NEWTON Study of EG-1962 for Improvement of Outcome after Ruptured Brain Aneurysm
Jun 5 14
Edge Therapeutics announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962. The NEWTON (Nimodipine microparticles to Enhance recovery While reducing TOxicity after subarachNoid hemorrhage) study is evaluating the safety, tolerability and pharmacokinetics of EG-1962 compared to the current standard of care, oral nimodipine, in patients with aneurysmal subarachnoid hemorrhage (aSAH). The company is also assessing patient functional outcomes at 30 and 90 days, which it believes will be indicative of the potential efficacy of EG-1962. EG-1962 is a novel polymeric nimodipine microparticle utilizing Edge's proprietary Precisa(TM) development platform and is being developed to improve patient outcome after aSAH, also commonly referred to as ruptured brain aneurysm.
Edge Therapeutics, Inc. Announces Opening of New Corporate Headquarters
Apr 8 14
Edge Therapeutics, Inc. announced that the company has opened its new corporate headquarters at 200 Connell Drive, Suite 1600, Berkeley Heights, New Jersey.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 8, 2014